, Volume 64, Issue 1, pp 14–30 | Cite as

Novel PET tracers: added value for endocrine disorders

  • Sébastien Bergeret
  • Judith Charbit
  • Catherine Ansquer
  • Géraldine Bera
  • Philippe Chanson
  • Charlotte Lussey-LepoutreEmail author


Nuclear medicine has been implicated in the diagnosis and treatment of endocrine disorders for several decades. With recent development of PET tracers, functional imaging now plays a major role in endocrine tumors enabling with high performance to their localization, characterization, and staging. Besides 18F-FDG, which may be used in the management and follow-up of endocrine tumors, new tracers have emerged, such as 18F-DOPA for neuroendocrine tumors (NETs) (medullary thyroid carcinoma, pheochromocytomas and paragangliomas and well-differentiated NETs originating from the midgut) and 18F-Choline in the field of primary hyperparathyroidism. Moreover, some peptides such as somatostatin analogs can also be used for peptide receptor radionuclide therapy. In this context, Gallium-68 labeled somatostatin analogs (68Ga-SSA) can help to tailor therapeutic choices and follow the response to treatment in the so-called “theranostic” approach. This review emphasizes the usefulness of these three novel PET tracers (18F-Choline, 18F-FDOPA, and 68Ga-SSA) for primary hyperparathyroidism and neuroendocrine tumors.


PET/CT Neuroendocrine tumors Primary hyperparathyroidism 18F-Choline 18F-FDOPA Gallium-68 Somatostatin 18F-FDG 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

All patients signed an inform consent stipulating that their images could be used in a research context after anonymized.


  1. 1.
    R. Boellaard, R. Delgado-Bolton, W.J.G. Oyen et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med Mol. Imaging 42, 328–354 (2015). CrossRefPubMedGoogle Scholar
  2. 2.
    V. Cuccurullo, G.D. Di Stasio, L. Evangelista, G. Castoria, L. Mansi, Biochemical and pathophysiological premises to positron emission tomography with Choline radiotracers. J. Cell. Physiol. 232, 270–275 (2017). CrossRefPubMedGoogle Scholar
  3. 3.
    C. Lussey-Lepoutre, E. Hindié, F. Montravers et al. The current role of 18F-FDOPA PET for neuroendocrine tumor imaging. Médecine Nucl. 40, 20–30 (2016). CrossRefGoogle Scholar
  4. 4.
    J.J.M. Teunissen, D.J. Kwekkeboom, R. Valkema, E.P. Krenning, Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr. Relat. Cancer 18(Suppl 1), S27–S51 (2011). CrossRefPubMedGoogle Scholar
  5. 5.
    I.M. Modlin, K. Oberg, D.C. Chung et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9, 61–72 (2008). CrossRefPubMedGoogle Scholar
  6. 6.
    J.-Y. Scoazec, A. Couvelard, Ppour le réseau TENpath (réseau national d’expertise pour le diagnostic anatomopathologique des tumeurs neuroendocrines malignes de l’adulte, sporadiques et familiales). [The new WHO classification of digestive neuroendocrine tumors]. Ann. Pathol. 31, 88–92 (2011). CrossRefPubMedGoogle Scholar
  7. 7.
    A. Dolcetta-Capuzzo, V. Villa, L. Albarello et al. Gastroenteric neuroendocrine neoplasms classification: comparison of prognostic models. Cancer 119, 36–44 (2013). CrossRefPubMedGoogle Scholar
  8. 8.
    G. Klöppel, Neuroendocrine neoplasms: dichotomy, origin and classifications. Visc. Med. 33, 324–330 (2017). CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    J. Strosberg, G. El-Haddad, E. Wolin et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017). CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    M.M. Graham, X. Gu, T. Ginader, P. Breheny, J.J. Sunderland, 68Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and metaanalysis. J. Nucl. Med. 58, 1452–1458 (2017). CrossRefPubMedGoogle Scholar
  11. 11.
    S.A. Deppen, J. Blume, A.J. Bobbey et al. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J. Nucl. Med. 57, 872–878 (2016). CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    F. Montravers, D. Grahek, K. Kerrou et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J. Nucl. Med. 47, 1455–1462 (2006)PubMedGoogle Scholar
  13. 13.
    A. Imperiale, E. Rust, S. Gabriel et al. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. J. Nucl. Med. 55, 367–372 (2014). CrossRefPubMedGoogle Scholar
  14. 14.
    M. Fani, G.P. Nicolas, D. Wild, Somatostatin receptor antagonists for imaging and therapy. J. Nucl. Med. 58(Suppl 2), 61S–66S (2017). CrossRefPubMedGoogle Scholar
  15. 15.
    G.P. Nicolas, N. Schreiter, F. Kaul et al. Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J. Nucl. Med. 59, 915–921 (2018). CrossRefPubMedGoogle Scholar
  16. 16.
    T.R. Halfdanarson, K.G. Rabe, J. Rubin, G.M. Petersen, Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann. Oncol. J. Eur. Soc. Med Oncol. 19, 1727–1733 (2008). CrossRefGoogle Scholar
  17. 17.
    H. Ahlström, B. Eriksson, M. Bergström, P. Bjurling, B. Långström, K. Oberg, Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 195, 333–337 (1995). CrossRefPubMedGoogle Scholar
  18. 18.
    F. Montravers, K. Kerrou, V. Nataf et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J. Clin. Endocrinol. Metab. 94, 1295–1301 (2009). CrossRefPubMedGoogle Scholar
  19. 19.
    O.C. Neels, K.P. Koopmans, P.L. Jager et al. Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells. Cancer Res. 68, 7183–7190 (2008). CrossRefPubMedGoogle Scholar
  20. 20.
    S. Kauhanen, M. Seppänen, P. Nuutila, Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomography. J. Clin. Oncol. Oncol. 26, 5307–5308 (2008). author reply5308-5309CrossRefGoogle Scholar
  21. 21.
    A. Imperiale, F. Sebag, M. Vix et al. 18F-FDOPA PET/CT imaging of insulinoma revisited. Eur. J. Nucl. Med. Mol. Imaging 42, 409–418 (2015). CrossRefPubMedGoogle Scholar
  22. 22.
    A. Imperiale, T. Bahougne, B. Goichot, P. Bachellier, D. Taïeb, I.J. Namer, Dynamic 18F-FDOPA PET findings after carbidopa premedication in 2 adult patients with insulinoma-related hyperinsulinemic hypoglycemia. Clin. Nucl. Med. 40, 682–684 (2015). CrossRefPubMedGoogle Scholar
  23. 23.
    A. Imperiale, P. Addeo, G. Averous, I.J. Namer, P. Bachellier, Solid pseudopapillary pancreatic tumor mimicking a neuroendocrine neoplasm on 18F-FDOPA PET/CT. J. Clin. Endocrinol. Metab. 98, 2643–2644 (2013). CrossRefPubMedGoogle Scholar
  24. 24.
    R. Kumar, P. Sharma, P. Garg et al. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur. Radiol. 21, 2408–2416 (2011). CrossRefPubMedGoogle Scholar
  25. 25.
    C. Schmid-Tannwald, C.M. Schmid-Tannwald, J.N. Morelli et al. Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Eur. J. Nucl. Med. Mol. Imaging 40, 897–907 (2013). CrossRefPubMedGoogle Scholar
  26. 26.
    P. Sharma, S. Arora, V.S. Dhull et al. Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors. Abdom. Imaging 40, 299–309 (2015). CrossRefPubMedGoogle Scholar
  27. 27.
    P. Sharma, S. Arora, S. Karunanithi et al. Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma. Q J. Nucl. Med Mol. Imaging 60, 69–76 (2016)PubMedGoogle Scholar
  28. 28.
    V. Prasad, A. Sainz-Esteban, R. Arsenic et al. Role of (68)Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study. Eur. J. Nucl. Med. Mol. Imaging 43, 1593–1600 (2016). CrossRefPubMedGoogle Scholar
  29. 29.
    J. Bertherat, F. Tenenbaum, K. Perlemoine et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J. Clin. Endocrinol. Metab. 88, 5353–5360 (2003). CrossRefPubMedGoogle Scholar
  30. 30.
    Y. Luo, Q. Pan, S. Yao et al. Glucagon-like peptide-1 receptor PET/CT with 68Ga-NOTA-exendin-4 for detecting localized insulinoma: a prospective cohort study. J. Nucl. Med. 57, 715–720 (2016). CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    E. Christ, D. Wild, S. Ederer et al. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes Endocrinol. 1, 115–122 (2013). CrossRefPubMedGoogle Scholar
  32. 32.
    K. Antwi, M. Fani, T. Heye et al. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. Eur. J. Nucl. Med. Mol. Imaging 45, 2318–2327 (2018). CrossRefPubMedGoogle Scholar
  33. 33.
    A. Haug, C.J. Auernhammer, B. Wängler et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 36, 765–770 (2009). CrossRefPubMedGoogle Scholar
  34. 34.
    D. Putzer, M. Gabriel, D. Kendler et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J. Nucl. Med Mol. Imaging 54, 68–75 (2010)PubMedGoogle Scholar
  35. 35.
    N. Naswa, P. Sharma, R. Soundararajan et al. Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. Abdom. Imaging 38, 552–560 (2013). CrossRefPubMedGoogle Scholar
  36. 36.
    M. Anlauf, B. Sipos, I. Boeck et al. [Neuroendocrine neoplasms of the distal jejunum and ileum]. Pathology 35, 283–293 (2014). quiz 294CrossRefGoogle Scholar
  37. 37.
    S. Balogova, J.-N. Talbot, V. Nataf et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur. J. Nucl. Med. Mol. Imaging 40, 943–966 (2013). CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    K.P. Koopmans, E.G.E. de Vries, I.P. Kema et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 7, 728–734 (2006). CrossRefPubMedGoogle Scholar
  39. 39.
    H. Ilhan, W.P. Fendler, C.C. Cyran et al. Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum. Ann. Surg. Oncol. 22, 164–171 (2015). CrossRefPubMedGoogle Scholar
  40. 40.
    V. Ambrosini, P. Tomassetti, P. Castellucci et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 35, 1431–1438 (2008). CrossRefPubMedGoogle Scholar
  41. 41.
    T. Binderup, U. Knigge, A. Loft et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J. Nucl. Med.51, 704–712 (2010). CrossRefPubMedGoogle Scholar
  42. 42.
    T.H. Tan, C.Y. Boey, B.N. Lee, Impact of 68Ga-DOTA-peptide PET/CT on the management of gastrointestinal neuroendocrine tumour (GI-NET): Malaysian National Referral Centre Experience. Nucl. Med. Mol. Imaging 52, 119–124 (2018). CrossRefPubMedGoogle Scholar
  43. 43.
    T. Belhocine, J. Foidart, P. Rigo et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl. Med. Commun. 23, 727–734 (2002)CrossRefPubMedGoogle Scholar
  44. 44.
    E. Rust, F. Hubele, E. Marzano et al. Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice. Cancer Imaging. 12, 173–184 (2012). CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    R. Abgral, S. Leboulleux, D. Déandreis et al. Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 ( ≥ 10%) well-differentiated endocrine carcinoma staging. J. Clin. Endocrinol. Metab. 96, 665–671 (2011). CrossRefPubMedGoogle Scholar
  46. 46.
    G. Luo, Z. Liu, M. Guo et al. (18)F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. Int. J. Oncol. 45, 1531–1536 (2014). CrossRefPubMedGoogle Scholar
  47. 47.
    S. Partelli, M. Rinzivillo, A. Maurizi et al. The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors. Neuroendocrinology 100, 293–299 (2014). CrossRefPubMedGoogle Scholar
  48. 48.
    E. Garin, F. Le Jeune, A. Devillers et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J. Nucl. Med. 50, 858–864 (2009). CrossRefPubMedGoogle Scholar
  49. 49.
    M. Bucau, A. Laurent-Bellue, N. Poté et al. 18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation. Neuroendocrinology 106, 274–282 (2018). CrossRefPubMedGoogle Scholar
  50. 50.
    E.M. Tabaksblat, S.W. Langer, U. Knigge et al. Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: state of the art. Acta Oncol. Stockh. Swed. 55, 3–14 (2016). CrossRefGoogle Scholar
  51. 51.
    B.I. Gustafsson, M. Kidd, A. Chan, M.V. Malfertheiner, I.M. Modlin, Bronchopulmonary neuroendocrine tumors. Cancer 113, 5–21 (2008). CrossRefPubMedGoogle Scholar
  52. 52.
    C. Ansquer, D. Taieb, F. Montravers, F. Tenenbaum, PET imaging with 68 gallium labelled somatostatin analogues in the evaluation of neuroendocrine tumours (NETs). Accessed 16 June 2018.
  53. 53.
    M.F. Bozkurt, I. Virgolini, S. Balogova et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur. J. Nucl. Med. Mol. Imaging 44, 1588–1601 (2017). CrossRefPubMedGoogle Scholar
  54. 54.
    M. Rodrigues, T. Traub-Weidinger, S. Li, B. Ibi, I. Virgolini, Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 33, 532–540 (2006). CrossRefPubMedGoogle Scholar
  55. 55.
    V. Ambrosini, P. Castellucci, D. Rubello et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl. Med. Commun. 30, 281–286 (2009). CrossRefPubMedGoogle Scholar
  56. 56.
    G. Treglia, P. Castaldi, G. Rindi, A. Giordano, V. Rufini, Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42, 80–87 (2012). CrossRefPubMedGoogle Scholar
  57. 57.
    K. Oberg, Molecular imaging radiotherapy: theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics 2, 448–458 (2012). CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    I. Kayani, B.G. Conry, A.M. Groves et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J. Nucl. Med. 50, 1927–1932 (2009). CrossRefPubMedGoogle Scholar
  59. 59.
    T. Jindal, A. Kumar, B. Venkitaraman et al. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids. Cancer Imaging 11, 70–75 (2011). CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    B. Venkitaraman, S. Karunanithi, A. Kumar, G.C. Khilnani, R. Kumar, Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur. J. Nucl. Med. Mol. Imaging 41, 856–864 (2014). CrossRefPubMedGoogle Scholar
  61. 61.
    N. Pandit, M. Gonen, L. Krug, S.M. Larson, Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 30, 78–84 (2003). CrossRefPubMedGoogle Scholar
  62. 62.
    U.-F. Pape, A. Perren, B. Niederle et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 95, 135–156 (2012). CrossRefPubMedGoogle Scholar
  63. 63.
    G. Capurso, M. Rinzivillo, R. Bettini, L. Boninsegna, G. Delle Fave, M. Falconi, Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br. J. Surg. 99, 1480–1486 (2012). CrossRefPubMedGoogle Scholar
  64. 64.
    M.D. Miljković, M. Girotra, R.R. Abraham, R.B. Erlich, Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. Dig. Dis. Sci. 57, 9–18 (2012). CrossRefPubMedGoogle Scholar
  65. 65.
    V. Prasad, V. Ambrosini, M. Hommann, D. Hoersch, S. Fanti, R.P. Baum, Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur. J. Nucl. Med. Mol. Imaging 37, 67–77 (2010). CrossRefPubMedGoogle Scholar
  66. 66.
    N. Naswa, P. Sharma, A. Kumar et al. 68Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin. Nucl. Med. 37, 245–251 (2012). CrossRefPubMedGoogle Scholar
  67. 67.
    O. Alonso, M. Rodríguez-Taroco, E. Savio, C. Bentancourt, J.P. Gambini, H. Engler, 68)Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin. Ann. Nucl. Med. 28, 638–645 (2014). CrossRefPubMedGoogle Scholar
  68. 68.
    G. Treglia, C. Aktolun, A. Chiti et al. The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine. Eur. J. Nucl. Med. Mol. Imaging 43, 1486–1490 (2016). CrossRefPubMedGoogle Scholar
  69. 69.
    S. Leboulleux, E. Baudin, J.-P. Travagli, M. Schlumberger, Medullary thyroid carcinoma. Clin. Endocrinol. (Oxf.). 61, 299–310 (2004). CrossRefPubMedGoogle Scholar
  70. 70.
    A.L. Giraudet, D. Vanel, S. Leboulleux et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J. Clin. Endocrinol. Metab. 92, 4185–4190 (2007). CrossRefPubMedGoogle Scholar
  71. 71.
    G. Treglia, P. Castaldi, M.F. Villani et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 39, 569–580 (2012). CrossRefPubMedGoogle Scholar
  72. 72.
    A.R. Romero-Lluch, J.I. Cuenca-Cuenca, R. Guerrero-Vázquez et al. Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur. J. Nucl. Med. Mol. Imaging 44, 2004–2013 (2017). CrossRefPubMedGoogle Scholar
  73. 73.
    H.H.G. Verbeek, J.T.M. Plukker, K.P. Koopmans et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J. Nucl. Med. 53, 1863–1871 (2012). CrossRefPubMedGoogle Scholar
  74. 74.
    F. Caobelli, A. Chiaravalloti, L. Evangelista et al. Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid. Ann. Nucl. Med. 32, 7–15 (2018). CrossRefPubMedGoogle Scholar
  75. 75.
    A. Archier, C. Heimburger, C. Guerin et al. 18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 43, 1027–1033 (2016). CrossRefPubMedGoogle Scholar
  76. 76.
    A. Sesti, M. Mayerhoefer, M. Weber et al. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET. Anticancer Res. 34, 6647–6654 (2014)PubMedGoogle Scholar
  77. 77.
    S. Kauhanen, C. Schalin-Jäntti, M. Seppänen et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J. Nucl. Med. 52, 1855–1863 (2011). CrossRefPubMedGoogle Scholar
  78. 78.
    M. Luster, W. Karges, K. Zeich et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 20, 527–533 (2010). CrossRefPubMedGoogle Scholar
  79. 79.
    M.C. Marzola, M.R. Pelizzo, M. Ferdeghini et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur. J. Surg. Oncol. 36, 414–421 (2010). CrossRefPubMedGoogle Scholar
  80. 80.
    M. Beheshti, S. Pöcher, R. Vali et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur. Radiol. 19, 1425–1434 (2009). CrossRefPubMedGoogle Scholar
  81. 81.
    K.P. Koopmans, J.W.B. de Groot, J.T.M. Plukker et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J. Nucl. Med. 49, 524–531 (2008). CrossRefPubMedGoogle Scholar
  82. 82.
    B. Beuthien-Baumann, A. Strumpf, J. Zessin, J. Bredow, J. Kotzerke, Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 34, 1604–1609 (2007). CrossRefPubMedGoogle Scholar
  83. 83.
    S. Hoegerle, C. Altehoefer, N. Ghanem, I. Brink, E. Moser, E. Nitzsche, 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur. J. Nucl. Med. 28, 64–71 (2001)CrossRefPubMedGoogle Scholar
  84. 84.
    G. Treglia, V. Rufini, M. Salvatori, A. Giordano, L. Giovanella, PET imaging in recurrent medullary thyroid carcinoma. Int. J. Mol. Imaging 2012, 324686 (2012). CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    K. Slavikova, F. Montravers, G. Treglia et al. What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma? Curr. Radiopharm. 6, 96–105 (2013)CrossRefPubMedGoogle Scholar
  86. 86.
    M. Soussan, V. Nataf, K. Kerrou et al. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl. Med. Commun. 33, 775–779 (2012). CrossRefPubMedGoogle Scholar
  87. 87.
    S.A. Wells, S.L. Asa, H. Dralle et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid J. Am. Thyroid Assoc. 25, 567–610 (2015). CrossRefGoogle Scholar
  88. 88.
    American Thyroid Association Guidelines Task Force, R.T. Kloos, C. Eng et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid J. Am. Thyroid Assoc. 19, 565–612 (2009). CrossRefGoogle Scholar
  89. 89.
    A. Oudoux, P.-Y. Salaun, C. Bournaud et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J. Clin. Endocrinol. Metab. 92, 4590–4597 (2007). CrossRefPubMedGoogle Scholar
  90. 90.
    J. Barbet, L. Campion, F. Kraeber-Bodéré, J.-F. Chatal; GTE Study Group, Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 90, 6077–6084 (2005). CrossRefPubMedGoogle Scholar
  91. 91.
    K. Pacak, S.H. Tella, Pheochromocytoma and Paraganglioma. ed. by L.J. De Groot, G. Chrousos, K. Dungan et al. Endotext. (, Inc., South Dartmouth (MA), 2000). Accessed 12 June 2018.
  92. 92.
    L. Amar, A. Servais, A.-P. Gimenez-Roqueplo, F. Zinzindohoue, G. Chatellier, P.-F. Plouin, Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J. Clin. Endocrinol. Metab. 90, 2110–2116 (2005). CrossRefPubMedGoogle Scholar
  93. 93.
    R.A. DeLellis, R.V. Lloyd, P.U. Heitz, World Health Organization classification of tumours pathology & genetics. Tumours Endocr. Organs. 151–155 (2004).Google Scholar
  94. 94.
    J. Favier, L. Amar, A.-P. Gimenez-Roqueplo, Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat. Rev. Endocrinol. 11, 101–111 (2015). CrossRefPubMedGoogle Scholar
  95. 95.
    D. Taïeb, K. Pacak, Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. Cell Tissue Res. 372, 393–401 (2018). CrossRefPubMedGoogle Scholar
  96. 96.
    D. Taïeb, H.J. Timmers, E. Hindié et al., EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur. J. Nucl. Med. Mol. Imaging 39, 1977–1995 (2012). CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    F. Pacini, M.G. Castagna, L. Brilli, G. Pentheroudakis; ESMO Guidelines Working Group, Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl 7), vii110–vii119 (2012). CrossRefPubMedGoogle Scholar
  98. 98.
    G. Treglia, F. Cocciolillo, C. de Waure et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 39, 1144–1153 (2012). CrossRefPubMedGoogle Scholar
  99. 99.
    S. Hoegerle, N. Ghanem, C. Altehoefer et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur. J. Nucl. Med. Mol. Imaging 30, 689–694 (2003). CrossRefPubMedGoogle Scholar
  100. 100.
    Timmers HJLM, C.C. Chen, J.A. Carrasquillo et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 94, 4757–4767 (2009). CrossRefGoogle Scholar
  101. 101.
    I. Janssen, C.C. Chen, D. Taieb et al. 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI. J. Nucl. Med. 57, 186–191 (2016). CrossRefPubMedGoogle Scholar
  102. 102.
    A. Archier, A. Varoquaux, P. Garrigue et al. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur. J. Nucl. Med. Mol. Imaging 43, 1248–1257 (2016). CrossRefPubMedGoogle Scholar
  103. 103.
    A. Kroiss, D. Putzer, A. Frech et al. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur. J. Nucl. Med. Mol. Imaging 40, 1800–1808 (2013). CrossRefPubMedGoogle Scholar
  104. 104.
    I. Janssen, E.M. Blanchet, K. Adams et al. Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin. Cancer Res. 21, 3888–3895 (2015). CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    C. Lepoutre-Lussey, C. Caramella, F. Bidault et al. Screening in asymptomatic SDHx mutation carriers: added value of 18F-FDG PET/CT at initial diagnosis and 1-year follow-up. Eur. J. Nucl. Med. Mol. Imaging 42, 868–876 (2015). CrossRefPubMedGoogle Scholar
  106. 106.
    J.P. Bilezikian, L. Bandeira, A. Khan, N.E. Cusano, Hyperparathyroidism. Lancet Lond. Engl. 391, 168–178 (2018). CrossRefGoogle Scholar
  107. 107.
    J.P. Bilezikian, M.L. Brandi, R. Eastell et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3561–3569 (2014). CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    A.A. Khan, D.A. Hanley, R. Rizzoli et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos. Int J. Establ Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA 28, 1–19 (2017). CrossRefGoogle Scholar
  109. 109.
    A.M. Laird, S.K. Libutti, Minimally invasive parathyroidectomy versus bilateral neck exploration for primary hyperparathyroidism. Surg. Oncol. Clin. N. Am. 25, 103–118 (2016). CrossRefPubMedGoogle Scholar
  110. 110.
    J.M. Ruda, C.S. Hollenbeak, B.C. Stack, A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol. Head Neck Surg. 132, 359–372 (2005). CrossRefPubMedGoogle Scholar
  111. 111.
    C.-Y. Lo, B.H. Lang, W.F. Chan, A.W.C. Kung, K.S.L. Lam, A prospective evaluation of preoperative localization by technetium-99m sestamibi scintigraphy and ultrasonography in primary hyperparathyroidism. Am. J. Surg. 193, 155–159 (2007). CrossRefPubMedGoogle Scholar
  112. 112.
    C. Ansquer, E. Mirallié, T. Carlier, H. Abbey-Huguenin, F. Aubron, F. Kraeber-Bodéré, Preoperative localization of parathyroid lesions. Value of 99mTc-MIBI tomography and factors influencing detection. Nukl. Nucl. Med. 47, 158–162 (2008)CrossRefGoogle Scholar
  113. 113.
    T. Carlier, A. Oudoux, E. Mirallié et al. 99mTc-MIBI pinhole SPECT in primary hyperparathyroidism: comparison with conventional SPECT, planar scintigraphy and ultrasonography. Eur. J. Nucl. Med. Mol. Imaging 35, 637–643 (2008). CrossRefPubMedGoogle Scholar
  114. 114.
    T. Cazaentre, F. Clivaz, F. Triponez, False-positive result in 18F-fluorocholine PET/CT due to incidental and ectopic parathyroid hyperplasia. Clin. Nucl. Med. 39, e328–e330 (2014). CrossRefPubMedGoogle Scholar
  115. 115.
    M. Hodolic, V. Huchet, S. Balogova et al. Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. Radiol. Oncol. 48, 228–234 (2014). CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    P. Mapelli, E. Busnardo, P. Magnani et al. Incidental finding of parathyroid adenoma with 11C-choline PET/CT. Clin. Nucl. Med. 37, 593–595 (2012). CrossRefPubMedGoogle Scholar
  117. 117.
    M. Orevi, N. Freedman, E. Mishani, M. Bocher, O. Jacobson, Y. Krausz, Localization of parathyroid adenoma by 11C-choline PET/CT: preliminary results. Clin. Nucl. Med. 39, 1033–1038 (2014). CrossRefPubMedGoogle Scholar
  118. 118.
    L. Lezaic, S. Rep, M.J. Sever, T. Kocjan, M. Hocevar, J. Fettich, 18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur. J. Nucl. Med. Mol. Imaging 41, 2083–2089 (2014). CrossRefPubMedGoogle Scholar
  119. 119.
    M. Hocevar, L. Lezaic, S. Rep et al. Focused parathyroidectomy without intraoperative parathormone testing is safe after pre-operative localization with 18F-Fluorocholine PET/CT. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 43, 133–137 (2017). CrossRefGoogle Scholar
  120. 120.
    N. Thanseer, S.K. Bhadada, A. Sood et al. Comparative effectiveness of ultrasonography, 99mTc-Sestamibi, and 18F-Fluorocholine PET/CT in detecting parathyroid adenomas in patients with primary hyperparathyroidism. Clin. Nucl. Med. 42, e491–e497 (2017). CrossRefPubMedGoogle Scholar
  121. 121.
    S. Rep, M. Hocevar, J. Vaupotic, U. Zdesar, K. Zaletel, L. Lezaic, 18F-choline PET/CT for parathyroid scintigraphy: significantly lower radiation exposure of patients in comparison to conventional nuclear medicine imaging approaches. J. Radiol. Prot. 38, 343–356 (2018). CrossRefPubMedGoogle Scholar
  122. 122.
    A.O.J. Bergenfelz, G. Wallin, S. Jansson et al. Results of surgery for sporadic primary hyperparathyroidism in patients with preoperatively negative sestamibi scintigraphy and ultrasound. Langenbecks Arch. Surg. 396, 83–90 (2011). CrossRefPubMedGoogle Scholar
  123. 123.
    B.M. Dy, M.L. Richards, B.J. Vazquez, G.B. Thompson, D.R. Farley, C.S. Grant, Primary hyperparathyroidism and negative Tc99 sestamibi imaging: to operate or not? Ann. Surg. Oncol. 19, 2272–2278 (2012). CrossRefPubMedGoogle Scholar
  124. 124.
    L. Michaud, A. Burgess, V. Huchet et al. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J. Clin. Endocrinol. Metab. 99, 4531–4536 (2014). CrossRefPubMedGoogle Scholar
  125. 125.
    L. Michaud, S. Balogova, A. Burgess et al. A pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine (Baltimore) 94, e1701 (2015). CrossRefGoogle Scholar
  126. 126.
    S. Grimaldi, J. Young, P. Kamenicky et al., Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. Eur. J. Nucl. Med. Mol. Imaging. (2018).
  127. 127.
    S. Rep, L. Lezaic, T. Kocjan et al. Optimal scan time for evaluation of parathyroid adenoma with [(18)F]-fluorocholine PET/CT. Radiol. Oncol. 49, 327–333 (2015). CrossRefPubMedPubMedCentralGoogle Scholar
  128. 128.
    W.P. Kluijfhout, W.M.C.M. Vorselaars, S.A.M. van den Berk et al. Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: a multicenter study from the Netherlands. Nucl. Med. Commun. 37, 1246–1252 (2016). CrossRefPubMedGoogle Scholar
  129. 129.
    W.P. Kluijfhout, J.D. Pasternak, J.E. Gosnell et al. 18F fluorocholine PET/MR imaging in patients with primary hyperparathyroidism and inconclusive conventional imaging: a prospective pilot study. Radiology 284, 460–467 (2017). CrossRefPubMedGoogle Scholar
  130. 130.
    E. Quak, D. Blanchard, B. Houdu et al. F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. Eur. J. Nucl. Med. Mol. Imaging 45, 658–666 (2018). CrossRefPubMedGoogle Scholar
  131. 131.
    M. Beheshti, L. Hehenwarter, Z. Paymani et al. 18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. Eur. J. Nucl. Med. Mol. Imaging 45, 1762–1771 (2018). CrossRefPubMedPubMedCentralGoogle Scholar
  132. 132.
    S. Fischli, I. Suter-Widmer, B.T. Nguyen et al. The significance of 18F-Fluorocholine-PET/CT as localizing imaging technique in patients with primary hyperparathyroidism and negative conventional imaging. Front. Endocrinol. 8, 380 (2017). CrossRefGoogle Scholar
  133. 133.
    G.F. Huber, M. Hüllner, C. Schmid et al. Benefit of 18F-fluorocholine PET imaging in parathyroid surgery. Eur. Radiol. 28, 2700–2707 (2018). CrossRefPubMedGoogle Scholar
  134. 134.
    C. Amadou, G. Bera, M. Ezziane et al., 18F-Fluorocholine PET/CT and parathyroid 4D computed tomography for primary hyperparathyroidism: the challenge of reoperative patients. World J. Surg. (2019).
  135. 135.
    O. Koulouri, N. Kandasamy, A.C. Hoole et al. Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI. Eur. J. Endocrinol. 175, 485–498 (2016). CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Sébastien Bergeret
    • 1
  • Judith Charbit
    • 1
  • Catherine Ansquer
    • 2
    • 3
  • Géraldine Bera
    • 1
    • 4
  • Philippe Chanson
    • 5
    • 6
  • Charlotte Lussey-Lepoutre
    • 1
    • 7
    Email author
  1. 1.Sorbonne University, Nuclear Medicine DepartmentPitié-Salpêtrière HospitalParisFrance
  2. 2.Nuclear Medicine DepartmentCHU-Hôtel DieuNantes Cedex1France
  3. 3.CIRCINA INSERMAngers UniversityNantesFrance
  4. 4.INSERM U1146, Laboratoire d’imagerie Biomedicale (LIB)Sorbonne UniversityParisFrance
  5. 5.Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Service d’Endocrinologie et des Maladies de la ReproductionCentre de Référence des Maladies Rares de l’HypophyseLe Kremlin BicêtreFrance
  6. 6.INSERM UMR S1185, Fac Med Paris SudUniv Paris-Sud, Université Paris-SaclayLe Kremlin-BicêtreFrance
  7. 7.INSERM U970Georges Pompidou European Hospital Cardiovascular Research CenterParisFrance

Personalised recommendations